145 related articles for article (PubMed ID: 38787899)
1. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.
Ansaripour A; Uyl-de Groot CA; Redekop WK
Pharmacoeconomics; 2018 Jan; 36(1):91-103. PubMed ID: 28795341
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
[No Abstract] [Full Text] [Related]
8. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
Ioannou SS; Marcou Y; Kakouri E; Talias MA
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
14. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
Lang HC; Chen HW; Chiou TJ; Chan AL
J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil.
Botelho CH; Estevez-Diz MDP; Campolina AG
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):63-72. PubMed ID: 34319216
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
Leung W; Kvizhinadze G; Nair N; Blakely T
PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
19. Does Trastuzumab Offer Good Value for Money for Breast Cancer Patients with Metastasis in Indonesia?
Kristin E; Endarti D; Khoe LC; Pratiwi WR; Pinzon RT; Febrinasari RP; Yasmina A; Nugrahaningsih DAA; Taroeno-Hariadi KW; Karsono R; Sudarsa IW; Prenggono MD; Herlinawaty E; Komaryani K; Hidayat B; Nadjib M
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2441-2447. PubMed ID: 35901352
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
